Adaptimmune Therapeutics Pipeline
| Drug | Indication | Phase |
|---|
| ADP-600 | PRAME-expressing cancers (synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian, head & neck) | Indication Enabling |
| ADP-520 | CD70-expressing cancers (hematological malignancies, AML, lymphoma, RCC) | Indication Enabling |